Table 4.
Cost-Effectiveness Results
| Cost* | Incremental Cost | Effectiveness** | Incremental Effectiveness | ICER | Cost per Event Avoided | Difference | |
|---|---|---|---|---|---|---|---|
| CNIC-Polypill | 4668 | −919 | 80.2 | −3.5 | Dominant | 5820 | −1464 |
| Monocomponents | 5587 | – | 76.7 | – | – | 7284 | – |
| CNIC-Polypill | 4668 | −1014 | 80.2 | −5.7 | Dominant | 5820 | −1806 |
| Equipotent | 5682 | – | 74.5 | – | – | 7627 | – |
| CNIC-Polypill | 4668 | −1348 | 80.2 | −7.0 | Dominant | 5820 | −2398 |
| Other therapies | 6016 | – | 73.2 | – | – | 8219 | – |
Notes: *Adjusted total cost. **Estimated as the percentage of patients without cardiovascular events.
Abbreviation: ICER, incremental cost–effectiveness ratio.